Clinical Trial Update: Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and tolerability of suprachoroidal CLS-AX injection after anti-VEGF therapy in neovascular age-related macular degeneration ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• CLS-AX

Snippet

Sponsor: Clearside Biomedical, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-21